Financials Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
29.03 USD -0.96% Intraday chart for Harmony Biosciences Holdings, Inc. -3.68% -10.12%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,057 2,493 3,268 1,892 1,649 - -
Enterprise Value (EV) 1 2,022 2,449 3,214 1,759 1,357 1,125 842.5
P/E ratio -14.6 x 73.5 x 18.6 x 15.2 x 12.5 x 7.55 x 5.82 x
Yield - - - - - - -
Capitalization / Revenue 12.9 x 8.16 x 7.46 x 3.25 x 2.32 x 1.96 x 1.67 x
EV / Revenue 12.7 x 8.02 x 7.34 x 3.02 x 1.91 x 1.34 x 0.85 x
EV / EBITDA 74.2 x 23 x 22.4 x 8.13 x 7.8 x 3.44 x 2.19 x
EV / FCF -677 x 24.9 x 22.3 x 8.03 x 7.58 x 4.5 x 2.52 x
FCF Yield -0.15% 4.01% 4.49% 12.5% 13.2% 22.2% 39.6%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 56,889 58,472 59,318 58,572 56,792 - -
Reference price 2 36.15 42.64 55.10 32.30 29.03 29.03 29.03
Announcement Date 3/25/21 2/28/22 2/21/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 159.7 305.4 437.9 582 711.6 842.3 989.6
EBITDA 1 27.26 106.4 143.6 216.4 174 326.8 384.6
EBIT 1 16.99 87.53 120.2 192 191.6 304 387.3
Operating Margin 10.63% 28.66% 27.45% 32.99% 26.92% 36.09% 39.14%
Earnings before Tax (EBT) 1 -36.94 37.43 104.7 173.4 173.9 297.7 387
Net income 1 -63.85 34.6 181.5 128.9 141 231.7 293.8
Net margin -39.97% 11.33% 41.44% 22.14% 19.82% 27.51% 29.69%
EPS 2 -2.480 0.5800 2.970 2.130 2.326 3.843 4.992
Free Cash Flow 1 -2.987 98.26 144.3 219.1 179 250 333.8
FCF margin -1.87% 32.17% 32.95% 37.64% 25.16% 29.68% 33.74%
FCF Conversion (EBITDA) - 92.38% 100.5% 101.24% 102.9% 76.5% 86.81%
FCF Conversion (Net income) - 284.01% 79.51% 170.02% 126.96% 107.9% 113.64%
Dividend per Share 2 - - - - - - -
Announcement Date 3/25/21 2/28/22 2/21/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 91.21 85.31 107 117.2 128.3 119.1 134.2 160.3 168.4 154.6 173.5 187.2 197.1 181.7 205
EBITDA - - - - - - 52.97 - - - - - - - -
EBIT 1 28.63 27.56 33.12 11.9 47.61 40.42 46.9 64.51 40.2 52.03 11.74 57.09 57 62.18 70.57
Operating Margin 31.39% 32.3% 30.94% 10.15% 37.11% 33.93% 34.95% 40.25% 23.87% 33.65% 6.77% 30.49% 28.91% 34.23% 34.43%
Earnings before Tax (EBT) 1 24.48 23.38 29.23 7.967 44.1 37.78 44.1 51.83 39.69 51.78 11.82 53.27 51.89 60.03 68.47
Net income 1 22.71 21.48 23.53 87.79 48.51 29.48 34.3 38.47 26.61 38.33 8.468 40.05 39.11 45.53 52.03
Net margin 24.9% 25.18% 21.99% 74.91% 37.81% 24.75% 25.56% 24% 15.8% 24.79% 4.88% 21.39% 19.84% 25.06% 25.38%
EPS 2 0.3800 0.3500 0.3900 1.440 0.7900 0.4800 0.5600 0.6300 0.4500 0.6700 0.1229 0.7243 0.7257 0.7533 0.8467
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/28/22 5/3/22 8/2/22 11/1/22 2/21/23 5/2/23 8/1/23 10/31/23 2/22/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 34.4 44.3 54.1 133 292 524 806
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -2.99 98.3 144 219 179 250 334
ROE (net income / shareholders' equity) - - - 29.6% 37.7% - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share 2 - - - 3.630 3.720 4.650 -
Capex 1 0 0.3 0.17 0.31 0.8 0.38 1.36
Capex / Sales 0% 0.1% 0.04% 0.05% 0.11% 0.05% 0.14%
Announcement Date 3/25/21 2/28/22 2/21/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
29.03 USD
Average target price
42.25 USD
Spread / Average Target
+45.54%
Consensus
  1. Stock Market
  2. Equities
  3. HRMY Stock
  4. Financials Harmony Biosciences Holdings, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW